DUBLIN--(BUSINESS WIRE)--The "Global Immunology Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
Global Immunology Partnering 2012 to 2018 provides the full collection of Immunology disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.
- Trends in Immunology partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Immunology partnering agreement structure
- Immunology partnering contract documents
- Top Immunology deals by value
- Most active Immunology dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.
The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
In addition, a comprehensive appendix is provided with each report of all Immunology partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Immunology technologies and products.
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Immunology dealmaking
Chapter 3 - Financial deal terms for Immunology partnering
Chapter 4 - Leading Immunology deals and dealmakers
Chapter 5 - Immunology contract document directory
Chapter 6 - Immunology dealmaking by therapeutic target
For more information about this report visit https://www.researchandmarkets.com/research/c8nb83/global_immunology?w=4